Updated KDIGO guidelines a catalyst for Natera, says Piper Sandler

Piper Sandler analyst David Westenberg noted that Kidney Disease Improving Global Outcomes, or KDIGO, just updated guidelines for Renacare in new Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease, or CKD. These guidelines contain statements supporting genetic testing to establish the cause of CKD for most patients with the condition, which will drive margins and profitability and is “one of the many catalysts Natera has,” the analyst tells investors. The firm, which thinks the average selling price for Renasight, Natera’s germline test that screens for the hereditary cause of CKD, could increase “well north of $1000/test,” says Natera remains its top pick in the space and reiterates an Overweight rating and $110 price target on the shares.